We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum p53 antibodies: predictors of survival in small-cell lung cancer?
- Authors
Murray, P V; Soussi, T; O’Brien, M E R; Smith, I E; Brossault, S; Norton, A; Ashley, S; Tavassoli, M
- Abstract
Serum p53 antibodies have been shown to be a poor prognostic marker in resected non-small-cell lung cancer (NSCLC), but studies in small-cell lung cancer (SCLC) have been contradictory. We have studied the incidence of p53 antibodies in a large SCLC cohort treated at one oncology centre and correlated the results with survival. 231 patients (63% male, median age 65), diagnosed and treated for SCLC between 1987 and 1994 at The Royal Marsden Hospital NHS Trust, had sera stored pretreatment. All samples were tested for p53 antibodies (p53-Ab) using a standardized ELISA technique with a selection of strongly ELISA positive, weakly ELISA positive and negative samples being confirmed with immunoprecipitation. 54 patients were positive for p53-Ab (23%). The presence of a high titre of p53-Ab (titre ratio >5) appears to be associated with a survival advantage with a relative risk of death of 1.71 (95% CI: 1.14-2.58) in those without the antibody (P = 0.02). This study, the largest homogenous group so far looking at p53-Ab in SCLC, suggests that p53 antibody detection may have a role in predicting outcome in this type of cancer.
- Subjects
TUMOR markers; LUNG cancer
- Publication
British Journal of Cancer, 2000, Vol 83, Issue 11, p1418
- ISSN
0007-0920
- Publication type
Article
- DOI
10.1054/bjoc.2000.1475